Clene Inc. Advances ALS Treatment Toward FDA Accelerated Approval
TL;DR
Clene announced progress on its CNM-Au8 program for ALS and MS, preparing for potential NDA submission, giving a competitive edge in the market.
CNM-Au8 improves survival and function in CNS cells by targeting mitochondrial function, NAD pathway, and reducing oxidative stress, supporting neurodegenerative disease treatment.
Clene's CNM-Au8 program shows significant survival improvement in severe ALS patients and Phase 2 results demonstrating remyelination and neuronal repair in MS, offering hope for better treatments.
Clene's new data demonstrates exciting advancements in improving survival for ALS patients and promoting neuronal repair in MS, showcasing cutting-edge research in neurodegenerative disease treatment.
Found this article helpful?
Share it with your network and spread the knowledge!
Biotechnology company Clene Inc. announced significant progress in its neurological disease treatment research, with promising developments for patients with amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS).
The company is preparing to submit a New Drug Application (NDA) under the FDA's Accelerated Approval pathway for ALS in the fourth quarter of 2025. Recent data demonstrated that their investigational therapy, CNM-Au8, substantially improved survival rates for patients with more advanced stages of ALS.
In addition to ALS research, Clene presented Phase 2 extension study results for MS, showing potential for remyelination and neuronal repair. The therapy targets mitochondrial function and the NAD pathway while reducing oxidative stress, offering a novel approach to treating neurodegenerative conditions.
Financially, Clene reported a first quarter net loss of $0.8 million, with $9.8 million in cash reserves sufficient to fund operations through the third quarter of 2025. The company's strategic focus on improving neurological treatments continues to drive its research and development efforts.
The potential FDA accelerated approval could represent a significant advancement in ALS treatment, offering hope for patients with limited therapeutic options. CNM-Au8's unique mechanism of action distinguishes it from current treatment approaches, potentially providing a breakthrough in managing this challenging neurodegenerative disease.
Curated from InvestorBrandNetwork (IBN)
